Suppr超能文献

维拉帕米对原发性高血压患者肾血浆流量、肾小球滤过率及血浆血管紧张素II、醛固酮和精氨酸加压素的影响

Effect of verapamil on renal plasma flow, glomerular filtration rate and plasma angiotensin II, aldosterone and arginine vasopressin in essential hypertension.

作者信息

Sørensen S S, Thomsen O O, Danielsen H, Pedersen E B

出版信息

Eur J Clin Pharmacol. 1985;29(3):257-61. doi: 10.1007/BF00544077.

Abstract

Renal plasma flow, glomerular filtration rate plasma angiotensin II, aldosterone and arginine vasopressin, free water clearance, blood pressure and body weight in 11 patients with mild to moderate hypertension were determined at the end of consecutive 6 week periods of administration of placebo and verapamil up to 120 mg t.i.d. Verapamil induced a 10% reduction in diastolic blood pressure. Compared with placebo none of the other parameters measured changed after treatment with verapamil. There was no significant correlation between blood pressure and arginine vasopressin in plasma. It is concluded that verapamil reduced blood pressure by vasodilatation without activation of the counterbalancing mechanisms commonly seen after treatment with vasodilating drugs, i.e. tachycardia, activation of the renin-angiotensin-aldosterone system, water and salt retention, and without affecting renal haemodynamics. AVP does not seem to be involved in blood pressure regulation in mild to moderate essential hypertension.

摘要

对11例轻至中度高血压患者,在连续6周服用安慰剂及每日3次、每次最多120 mg维拉帕米治疗结束时,测定其肾血浆流量、肾小球滤过率、血浆血管紧张素II、醛固酮及精氨酸加压素、自由水清除率、血压和体重。维拉帕米使舒张压降低了10%。与安慰剂相比,维拉帕米治疗后所测的其他参数均未改变。血浆中血压与精氨酸加压素之间无显著相关性。结论是,维拉帕米通过血管舒张降低血压,而未激活血管扩张药物治疗后常见的代偿机制,即心动过速、肾素-血管紧张素-醛固酮系统激活、水盐潴留,且未影响肾血流动力学。在轻至中度原发性高血压中,精氨酸加压素似乎不参与血压调节。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验